Latest Amyloid precursor protein secretase Stories
TorreyPines Therapeutics, a biopharmaceutical company, has agreed to sell its Alzheimer's disease genetics research program to Eisai for an upfront cash payment.
SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease.
CoMentis, Inc. and Astellas Pharma, Inc. announced today that the companies will present six abstracts related to CTS21166 (ASP1702), a beta-secretase inhibitor for the treatment of Alzheimer's disease, at the 2008 International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31.
By Anonymous Study details new molecular approach to preventing Alzheimer's. The April 24 Washington Post reported that German researchers have developed a new approach to the possible prevention of the molecular "debris" that is associated with the development of Alzheimer's disease.
Researchers with the University of Florida and the California Institute of Technology have developed a new strain of genetically modified mice that allow scientists to examine the potential usefulness of new therapies for Alzheimer's disease.
The route to a treatment for Alzheimer's disease may have become more straightforward with the discovery that a key enzyme known to have a major role in this disease is in fact part of a family of enzymes. Only some family members play a role in the progression of this brain-wasting illness, new research at the University of Toronto has found.
- A woman chauffeur.
- A woman who operates an automobile.